Surface Logix To Present At The 2006 Biotechnology Industry Organization (BIO) Investor Forum
BOSTON, Oct. 17 /PRNewswire/ -- Surface Logix Inc. announced that Jim Mahoney, President and Chief Executive Officer, will present an update of the company's drug development pipeline at the 2006 BIO Investor Forum on October 19, 2006 at 10:20 a.m. Pacific (1:20 p.m. Eastern) Time from The Palace Hotel in San Francisco.
Surface Logix Inc. currently has two programs in human clinical trials with a third program approaching its initial regulatory submission. Mr. Mahoney will discuss the latest results for SLx-2101, currently in Phase IIa, a second generation PDE5 inhibitor designed to address cardiovascular indications including Raynaud's Syndrome and Hypertension; and SLx-4090, soon to be in Phase IIa, a first in class enterocyte specific MTP inhibitor targeting unmet needs in dyslipidemia and metabolic disorders.
About Surface Logix Inc.
Surface Logix Inc. uses its expertise in biophysical chemistry to create new small molecule drugs that are optimized to meet the challenges of human physiology. The company is advancing multiple internal programs focused primarily on cardiovascular, metabolic, inflammatory and fibrotic diseases. For more information, please visit http://www.surfacelogix.com.
Contact: David H. Donabedian, Ph.D. Vice President, Business Development 617.746.8520 Media: Kari Watson MacDougall Biomedical Communications Inc. kwatson@macbiocom.com 508.647.0209
Surface Logix Inc.CONTACT: David H. Donabedian, Ph.D., Vice President, Business Developmentfor Surface Logix Inc., +1-617-746-8520, or Kari Watson of MacDougallBiomedical Communications Inc. for Surface Logix Inc., +1-508-647-0209,kwatson@macbiocom.com
Web site: http://www.surfacelogix.com/